BRAF V600E mutations are common in different tumor ... are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib ...

Patients presenting these mutations ... in our BRAF V600E models. BRAF inhibitors have revolutionized the treatment of BRAF-mutated metastatic colorectal cancer or melanoma, while KRAS inhibitors ...

V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer ... for unresectable or metastatic BRAF-positive melanoma and non-small cell lung cancer (NSCLC), and as a second ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead ... in 2018 as a treatment for advanced cases of melanoma. It has since been approved as a second ...

In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

One upcoming clinical trial will target the antigen the common BRAF V600E mutation with CD4 T cells in melanoma and other tumors. A second approach is the development of novel therapeutic cancer ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...

Braftovi is a targeted medicine aimed at a particular mutation, V600E, to the BRAF gene. BRAF mutations ... At the time, the two drugs were only cleared for melanoma. Pfizer broadened use to ...

"The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward ...